Evidence map›Paper›PMID 36436827›Full record

Observational studyESC heart failure2023

Prognostic value of plasma sAXL in patients with heart failure: insights from the DRAGON-HF trial.

Yifan Liu, Xiaoyu Wang, Xin Pan, Teng Ma, Yawei Xu, Qimao Fen, Muyesai Nijiati, Chen Chi, Yang Su, Xianling Zhang and 1 more

Registry-linked trialOpen access · goldAbstract readObservational StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in ESC heart failure, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03727828 (Diagnostic, Risk Stratification and Prognostic Value of Novel Biomarkers in Patients With Heart Failure), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03727828 unknown statusnot on this map

Diagnostic, Risk Stratification and Prognostic Value of Novel Biomarkers in Patients With Heart Failure: DRAGON-HF Study

TypeobservationalSponsorShanghai 10th People's HospitalRan2018 to 2021Enrolled3,000ConditionsHeart FailureArmsPatients with heart failure
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Yifan LiuDepartment of Cardiology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China.
Xiaoyu WangDepartment of Cardiology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.
Xin PanDepartment of Geriatrics, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China.
Teng MaDepartment of Cardiology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China.
Yawei XuDepartment of Cardiology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China.
Qimao FenShanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 200071, China.
Muyesai NijiatiDepartment of Cardiology, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, China.
Chen ChiDepartment of Cardiology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China.
Yang SuDepartment of Cardiology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China.
Xianling ZhangDepartment of Cardiology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China.
Dachun XuDepartment of Cardiology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China.ORCID https://orcid.org/0000-0002-4123-6613
Tongji University · CNPeople's Hospital of Xinjiang Uygur Autonomous Region · CNShanghai East Hospital · CNShanghai University of Traditional Chinese Medicine · CN

Funding

Clinical Research Plan of Shanghai Hospital Development Center SHDC2020CR3030BNational Natural Science Foundation of China 81770391
6 · The paper itself

Abstract

backgroundLittle is known about the predictive value of soluble AXL (sAXL) in heart failure (HF). This study aimed to describe the prognostic value of plasma sAXL in patients with symptomatic HF.

methodsThis is a multicentre observational prospective cohort study (Registration No. NCT03727828). Plasma sAXL were measured on admission. The primary endpoint is a composite of cardiovascular mortality and HF rehospitalization. Associations between plasma sAXL levels and clinical endpoints are described using Cox regression models and Kaplan-Meier methods.

resultsA total of 1030 symptomatic HF patients were enrolled in the study; the mean age (65% men) was 71 ± 12 years, with a median follow-up of 32 months (IQR: 26-41 months). The mean baseline sAXL levels were 20.03 ± 6.74 ng/mL. Plasma sAXL positively associated with NYHA classification and negatively associated with left ventricular ejection fraction (both P < 0.001). Cox regression showed that 1-SD increment of sAXL was associated with primary endpoint [HR (CI): 1.128 (1.024-1.242)], cardiovascular mortality [1.112 (1.032-1.198)], all-cause mortality [1.142 (1.057-1.234)], and HF rehospitalization [1.122 (1.030-1.224)] after adjustment for potential confounders including NT-proBNP. Kaplan-Meier curves revealed that patients with the highest sAXL levels were at the highest risk of primary endpoint events, cardiovascular mortality, and all-cause mortality (all P values < 0.001). Furthermore, both Kaplan-Meier method and Categorical analysis demonstrated that the combined use of sAXL and NT-proBNP were more likely to predict all-cause or cardiovascular mortality (both P < 0.001). Similar results were observed when separating patients with respect to left ventricular ejection fraction, namely, in HFrEF, HFmrEF, and HFpEF groups.

conclusionsPlasma sAXL concentrations are of great importance in predicting clinical outcomes in HF patients, independent of NT-proBNP, suggesting that sAXL is a promising prognostic marker for further study.

Indexed as

Heart FailureAgedAged, 80 and overBiomarkersFemaleHumansMaleMiddle AgedPrognosisProspective StudiesStroke VolumeVentricular Function, LeftBiomarkersBiomarkerHeart failurePrognosissAXL

Identifiers

PMID36436827
PMCPMC9871665
OpenAlexW4310278121

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.